JPMorgan believes Kyverna Therapeutics (KYTX)’ KYV-101 stands out as a competitive treatment option for stiff person syndrome with the potential to reverse the disease course. The firm also sees a significantly faster path to the commercial market compared to other target indications. Early data showcased KYV-101’s promise in addressing SPS and without any effective options, Kyverna “could carve an expedited course to the finish line,” the analyst tells investors in a research note. At a negative enterprise value, JPMorgan believes Kyverna “remains significantly under-valued.” It reiterates an Overweight rating on the shares.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna CMO Resignation Highlights Leadership Transition Impact
- Kyverna Therapeutics price target lowered to $6 from $7 at H.C. Wainwright
- Kyverna Therapeutics price target lowered to $24 from $44 at Wells Fargo
- Kyverna Therapeutics Reports Q3 Loss Amid Rising R&D Costs
- Kyverna Therapeutics anounces patient data on KYV-101